Characterization of Breg Cells (NCT02615951) | Clinical Trial Compass
CompletedNot Applicable
Characterization of Breg Cells
France100 participantsStarted 2015-10-02
Plain-language summary
Recently, it has been shown that B cells could also have regulatory functions through the secretion of interleukin 10 (IL-10). They are called the B regulatory cells (Breg). In the mouse model the most commonly used of rheumatoid arthritis, collagen-induced arthritis (CIA), the transfer Breg helps prevent the development of CIA and cure established arthritis. The investigators have recently shown that Breg were decreased in patients with RA compared to controls and that the rate of Breg was inversely correlated with disease activity and autoantibody. These results thus suggest that the lack of IL-10 secretion by B cells plays an important role in the pathophysiology of RA. Nevertheless, in humans, the Breg remain poorly understood. The main objective of this project is to better characterize the B capable of producing IL-10 both in subjects with RA and controls. Understanding which induces the secretion of IL-10 by B could allow to consider new therapeutic approaches in autoimmune diseases, including in RA.
The investigators therefore aim to identify nutrient transporters, chemokine receptors, genes and surface proteins differentially expressed between Breg and other B cells in patients with RA and in controls.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* RA responding to ACR/EULAR 2010 criteria
Exclusion Criteria:
* steroid\> 10 mg/d
* previous use of biological disease-modifying antirheumatic drug (DMARD)
* age\<18 years
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial studies a type of immune cell called regulatory B cells, or Breg cells, in people with rheumatoid arthritis — can you explain what role these cells might play in my condition and why understanding them matters for future treatments?
2Since this study is focused on identifying differences between Breg cells and other B cells rather than testing a treatment, would any findings from research like this potentially affect the treatment options available to me, and if so, on what timeline?
3This trial has already been completed — is there any published data or results from it that you think would be relevant to my case or to decisions we're making about my care?
4The study enrolled both healthy volunteers and people with rheumatoid arthritis, so it seems to be foundational, exploratory research rather than a therapy trial — does this mean the main benefit to participants was contributing to scientific knowledge rather than receiving a new treatment, and are there active treatment trials I should know about instead?
5Given that this research was looking at nutrient transporters and chemokine receptors on immune cells, is there any current or upcoming trial building on this kind of work that might eventually offer new therapeutic options for people with my diagnosis?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Identification of nutrient transporters' and of chemokine receptors' differentially expressed between Breg and other B cells in patients with RA
Timeframe: after analysis of the blood sample from the subject selected for the primary outcome mesure. Estimated at half a year after subject recruitement started